Timeline of Canadian research on Alzheimer’s and related Dementias

Back to main page

Years

[ 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1995 | 1993 | 1987 ]

2012

• (2011-2012) CIHR Investment in Alzheimer's and related dementias: $27.1 million.
• CIHR joins the EU Joint Programme on Neurodegenerative Disease Research. Canada is the first country out of the European Union to join.

2011

• Dr. Howard Feldman develops international guidelines for early detection of Alzheimer's disease.
• CIHR partners with European countries to fund Centres of Excellence in Neurodegeneration Research.
• CIHR partners with the National Science Foundation of China to fund team grants.
• (2010-2011) CIHR Investment in Alzheimer's and related dementias: $26.1 million.

2010

• CIHR partners with the UK Medical Research Council to establish and apply harmonized guidelines and technologies for research on neurodegenerative diseases.
• CIHR partners with the US National Institutes of Health on Alzheimer's Disease Neuroimaging Initiative.
• (2009-2010) CIHR Investment in Alzheimer's and related dementias: $24.4 million.

2009

• Dr. Alan C. Evans develops a platform for the processing and exchange of brain imaging data that will allow Alzheimer's disease and related dementias researchers globally to access and contribute to large imaging databases.
• (2008-2009) CIHR Investment in Alzheimer's and related dementias: $23.8 million.

2008

• Dr. Serge Gauthier develops a method to analyze behavioural problems associated with Alzheimer's disease.
• CIHR signs a co-operation agreement with France and Québec on diagnosis, treatment and management of patients with Alzheimer's disease.
• (2007-2008) CIHR Investment in Alzheimer's and related dementias: $22.1 million.

2007

• Dr. Howard Feldman and Dr. Ian MacKenzie identify a genetic defect involved in frontotemporal dementia and Alzheimer's disease.
• (2006-2007) CIHR Investment in Alzheimer's and related dementias: $22.6 million.

2006

• (2005-2006) CIHR Investment in Alzheimer's and related dementias: $20.7 million.

2005

• Drs. Vladimir Hachinski and Sandra Black help to achieve consensus to harmonize protocols for clinical, cognitive, imaging, and pathological evaluation of Vascular Cognitive Impairment, which are now being validated in several countries around the world. They also influence thinking on the important interactions between Alzheimer's and cerebrovascular disease.
• Dr. Ziad Nasreddine designs a standard assessment tool for mild cognitive impairment which is often a precursor of Alzheimer's disease.
• (2004-2005) CIHR Investment in Alzheimer's and related dementias: $17.5 million.

2004

• (2003-2004) CIHR Investment in Alzheimer's and related dementias: $15.5 million.

2003

• (2002-2003) CIHR Investment in Alzheimer's and related dementias: $14.6 million.

2002

• (2001-2002) CIHR Investment in Alzheimer's and related dementias: $13.1 million.

2001

• (2000-2001) CIHR Investment in Alzheimer's and related dementias: $8.9 million.

2000

• Dr. Peter St George-Hyslop develops a vaccine that prevents Alzheimer's disease in mice and advances our understanding of dementia.

1995

• Dr. Peter St George-Hyslop discovers and clones two genes, called presenilins, responsible for early-onset Alzheimer's disease.

1993

• Dr. Judes Poirier discovers the apolipoprotein E is a genetic risk factor for Alzheimer's disease.

1987

• Drs. Patrick and Edith McGeer develop the once heretical but now accepted concept that inflammation plays a role in the pathology of Alzheimer's disease.